Market research
ERIS.NSE Eris Lifesciences Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 184B
- P/E ratio
- 28.27
- Analyst target
- 1661.2
- Dividend yield
- 0.0%
- Beta
- -0.04
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE406M01024
- Market cap
- 184B
- P/E ratio
- 28.27
- Analyst target
- 1661.2
- Dividend yield
- 0.0%
- Beta
- -0.04
About
About Eris Lifesciences Limited
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti"diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ERIS.NSE discussion.
5 years, 4 months ago
Eris Lifesciences Limited is currently in a long term uptrend where the price is trading 24.3% above its 200 day moving average.
From a valuation standpoint, the stock is 44.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 6.9.
Eris Lifesciences Limited's total revenue rose by 14.5% to $3B since the same quarter in the previous year.
Its net income has increased by 42.0% to $902M since the same quarter in the previous year.
Based on the above factors, Eris Lifesciences Limited gets an overall score of 3/5.